Shared on 15 Aug 25
Fair value Decreased 21%Veru’s future P/E has increased and its net profit margin has declined, indicating deteriorating profitability expectations, but analysts maintain their fair value estimate unchanged at $25.00. What's in the News Veru announced a novel modified release oral formulation for enobosarm in chronic weight loss, achieving target pharmacokinetics and leveraging proprietary delivery technology with positive Phase 2b efficacy and safety data.
Shared on 24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 0.92%AnalystConsensusTarget made no meaningful changes to valuation assumptions.